Temperature-Dependent Phase Transition Microemulsions for Enhanced Transdermal Delivery of Finasteride and Silodosin

This study successfully developed and optimized ethanol-free microemulsion systems for the transdermal delivery of finasteride, showing that the predicted optimal formulations had physicochemical characteristics close to estimated values, without significant damage to treated hair fibers.

This study investigated a finasteride and oregano oil-loaded nano-cubosome gel formulation, finding it enhanced drug release and skin permeation and demonstrated synergistic antibacterial effects, suggesting potential for treating alopecia areata.

This study found that finasteride- and minoxidil-loaded nanoparticles in a gel improved skin permeability and drug retention, suggesting a promising approach for topical alopecia treatment with reduced dosing frequency and side effects.

This study found that finasteride microemulsions significantly increased skin permeability in vitro, highlighting the potential for enhanced delivery of this drug through the skin.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

Ethosomes improve finasteride delivery through skin for hair loss treatment.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.